Compare Mesoblast Limited (MESO) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Real Estate Index Fund ETF — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Vanguard Real Estate Index Fund ETF trades at $90.65 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 40.5× Mesoblast Limited's market cap, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| MESO | VNQ | |
|---|---|---|
Market Cap | $1.75B | $70.80B |
Volume | 239,027 | 6,073,580 |
Sector | Health | — |
52-Week High | $20.96 | $100.95 |
52-Week Low | $13.19 | $87.00 |
Typical Hold Time | 15 Days | 113 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
VNQ trades at $89.35, up 0.74% today but facing bearish technical signals with 14 sell signals versus 5 buy signals. The ETF has declined nearly 10% over the past month amid rising Treasury yields and Federal Reserve rate hikes, eroding its income appeal relative to safer alternatives. Recent institutional buying by State Street Corp and Envestnet suggests some value hunting despite sector headwinds.
Outlook remains challenged by interest rate sensitivity, though contrarian investors see opportunity in discounted REIT valuations. Key risks include continued rate hikes and property oversupply, while potential catalysts include yield stabilization and sector rotation if economic conditions improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
